Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · September 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05498428). This is a study registration, not published results. Lead sponsor: Janssen Research & Development, LLC. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 520 participants (ESTIMATED). Conditions: Carcinoma, Non-small-Cell Lung. Interventions: DRUG: Amivantamab; DRUG: Lazertinib; DRUG: Carboplatin; DRUG: Pemetrexed; DRUG: Direct Oral Anticoagulant (DOAC); DRUG: Low Molecular Weight Heparin (LMWH). Primary outcome measures: All Cohorts Except Cohort 4: Objective Response Rate (ORR) Based on Investigator Assessment (INV) , Up to 1 year 6 months; Cohort 4: Number of Participants with Adverse Events (AEs) , Up to approximately 4 years and 9 months; Cohort 4: Number of Participants with AEs by Severity , Up to approximately 4 years and 9 months; Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values , Up to approximately 4 years and 9 months; Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values by Severity , Up to approximately 4 years and 9 months. Brief summary: The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).